Our study demonstrated that CNPY3, a cochaperone of immune chaperone GRP94, was elevated in the majority of human cancers, and the overexpression of CNPY3 and GRP94 predicts an aggressive phenotype and poor clinical outcome. The gene discussed is HSP90B1; the disease is cancer.